STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRBP
  4. [Form 4] Corbus Pharmaceuticals Holdings, Inc. Insider Trading Activity

Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. director John Kenneth Jenkins reported an open-market sale of 4,800 shares of common stock on June 10, 2026 at a weighted average price of $7.9137 per share, executed under a Rule 10b5-1 trading plan. Following this sale, he directly holds 3,833 shares of common stock and 3,800 unvested RSUs subject to the grant’s vesting schedule.

Positive

  • None.

Negative

  • None.
Insider Jenkins John Kenneth
Role null
Sold 4,800 shs ($38K)
Type Security Shares Price Value
Sale Common Stock, par value $0.0001 per share 4,800 $7.9137 $38K
Holdings After Transaction: Common Stock, par value $0.0001 per share — 3,833 shares (Direct, null)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.
Shares sold 4,800 shares Open-market sale on June 10, 2026
Weighted average sale price $7.9137 per share Common stock sale on June 10, 2026
Price range of trades $7.71–$7.97 per share Multiple transactions underlying weighted average price
Shares held after transaction 3,833 shares Direct common stock ownership following sale
Unvested RSUs 3,800 units Unvested RSUs subject to vesting schedule
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSUs financial
"This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jenkins John Kenneth
(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS,INC.
500 RIVER RIDGE DRIVE
(Street)
NORWOOD MASSACHUSETTS 02062
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share06/10/2026S(1)4,800D$7.9137(2)3,833(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.
/s/ Meghan Houghton, attorney-in-fact for John Jenkins06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) report for John Kenneth Jenkins?

Corbus director John Kenneth Jenkins reported selling 4,800 shares of common stock in an open-market transaction. The sale took place on June 10, 2026, and is detailed in a Form 4 insider trading report filed with the Securities and Exchange Commission.

At what price did John Kenneth Jenkins sell Corbus Pharmaceuticals (CRBP) shares?

Jenkins sold 4,800 Corbus shares at a weighted average price of $7.9137 per share. Footnotes note multiple trades within a price range from $7.71 to $7.97, with the weighted average reported in the Form 4 transaction column.

How many Corbus Pharmaceuticals (CRBP) shares does John Kenneth Jenkins hold after the sale?

After the reported sale, Jenkins directly holds 3,833 shares of Corbus common stock. A footnote also states he has 3,800 unvested restricted stock units (RSUs), which remain subject to the grant’s existing vesting schedule as previously reported.

Was John Kenneth Jenkins’ Corbus Pharmaceuticals (CRBP) share sale pre-planned?

Yes. The Form 4 states the transaction was effected under a Rule 10b5-1 trading plan adopted on March 11, 2026. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary market-timed decisions.

What does the price range in John Kenneth Jenkins’ Corbus (CRBP) sale mean?

The filing explains the reported price is a weighted average, with underlying trades between $7.71 and $7.97 per share. Jenkins undertakes to provide full details on the number of shares sold at each separate price within this range upon request.